Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer

• Published in: British journal of cancer Vol. 109; no. 12; pp. 2980 - 2986
• Main Authors: Homma, A, Sakashita, T, Yoshida, D, Onimaru, R, Tsuchiya, K, Suzuki, F, Yasuda, K, Hatakeyama, H, Furusawa, J, Mizumachi, T, Kano, S, Inamura, N, Taki, S, Shirato, H, Fukuda, S
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.12.2013; Nature Publishing Group
• Subjects: 692/699/67/1059/485; 692/699/67/1059/99; 692/699/67/1536; Adult; Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer therapies; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - radiotherapy; Chemoradiotherapy; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Clinical Study; Disease; Disease-Free Survival; Drug dosages; Drug Resistance; Epidemiology; Female; Head & neck cancer; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - radiotherapy; Humans; Infusions, Intra-Arterial; Male; Maxillary Sinus Neoplasms - drug therapy; Maxillary Sinus Neoplasms - radiotherapy; Medical imaging; Medical sciences; Metastasis; Middle Aged; Molecular Medicine; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Oncology; Otorhinolaryngology. Stomatology; Patients; Radiation therapy; Radiation-Sensitizing Agents - administration & dosage; Radiation-Sensitizing Agents - adverse effects; Recurrence; Sinuses; Squamous Cell Carcinoma of Head and Neck; Surgery; Survival Analysis; Toxicity; Tumors; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology; Veins & arteries; Japan; radiotherapy; maxillary sinus; cisplatin; chemotherapy; intra-arterial; Antineoplastic agent; Malignant tumor; Radiotherapy; Artery; Cisplatin; Maxillary sinus cancer; Alkylating agent; Chemotherapy; Cancerology; Treatment; Perfusion; Blood vessel; Maxillary sinus; ENT disease; Paranasal sinus disease; Circulatory system; Cancer; Platinum II Complexes
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.2013.663

Background: The purpose of this study was to evaluate the efficacy of superselective cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with the squamous cell carcinoma of maxillary sinus (SCC-MS). Methods: Between 1999 and 2010, 54 patients were given superselective intra-arterial infusions of cisplatin (100–120 mg m −2 per week) with simultaneous intra-venous infusions of thiosulfate to neutralise cisplatin toxicity and conventional radiotherapy (65–70 Gy). Results: One patient (1.9%) was diagnosed with T2, 14 (25.9%) with T3, 27 (50%) with T4a, and 12 (22.2%) with T4b disease. Lymph-node involvement was present in 12 patients (22.2%). During the median follow-up period of 6.4 years, the 5-year local progression-free and overall survival rates were 65.8 and 67.9% for all patients, respectively. No patient died as a result of treatment toxicity or experienced a cerebrovascular accident. Osteonecrosis ( n =5), brain necrosis ( n =1), and ocular/visual problems ( n =14) were observed as late adverse reactions. Conclusion: We have shown excellent overall survival and local progression-free rate in SCC-MS patients treated by RADPLAT with acceptable rates of acute and late toxicity. A multi-institutional trial is needed to prove that this strategy is a feasible and effective approach for the treatment of SCC-MS.